UBS: Hansoh Pharmaceutical (03692.HK) Mo-Rez data positive in platinum-resistant ovarian cancer; maintains "Buy" rating with target price of HK$50.8

Zhitong Finance APP has learned that UBS has issued a research report stating it maintains a "Buy" rating and a target price of HK$50.8 for Hansoh Pharmaceutical (03692.HK). The bank noted that the updated data on Mo-Rez for the treatment of platinum-resistant ovarian cancer (PROC) presented at the European Society for Medical Oncology (ESMO) 2026 Congress, as well as the Phase 1 clinical data for HS-20122, were both positive.